RxDoctor Payments DataLook up a doctor →

April Lenz, APRN

Nurse Practitioner · Dayton, OHNPI 1538731724

Payments from drug & device makers

$10,947in general payments, 2019–2025

Across 622 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$964
  • Lilly USA, LLC$849
  • GSK$727
  • Pfizer$576
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$10,947100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,947 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$60,771
Medicare patients
176
Services billed
1,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$66,638
EliquisApixaban35$48,658
TrulicityDulaglutide41$47,505
JardianceEmpagliflozin42$43,623
MounjaroTirzepatide35$40,073
JanuviaSitagliptin Phosphate39$38,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$36,861
RybelsusSemaglutide20$33,904
Soliqua 100-33Insulin Glargine/Lixisenatide15$16,278
Spiriva RespimatTiotropium Bromide17$12,855
FarxigaDapagliflozin Propanediol14$11,565
MyrbetriqMirabegron11$11,131
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$9,514
Repatha SureclickEvolocumab11$9,410
BelsomraSuvorexant13$5,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$964$100,54272 claims
Lilly USA, LLCTrulicity, Mounjaro$849$87,57876 claims
Boehringer IngelheimJardiance, Spiriva Respimat$303$56,47859 claims
PfizerEliquis$576$48,65835 claims
MerckJanuvia, Belsomra$49$44,39552 claims
GSKTrelegy Ellipta$727$36,86131 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$161$16,27815 claims
AstraZenecaFarxiga$1,013$11,56514 claims
Astellas Pharma US IncMyrbetriq$101$11,13111 claims
AbbVieSynthroid$2,345$1,50852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →